Robert LeBoyer

Stock Analyst at Noble Capital Markets

(1.16)
# 3,512
Out of 5,090 analysts
18
Total ratings
31.25%
Success rate
-1.08%
Average return

Stocks Rated by Robert LeBoyer

Tonix Pharmaceuticals Holding
Mar 20, 2025
Reiterates: Outperform
Price Target: $70
Current: $19.64
Upside: +256.42%
Nutriband
Jan 22, 2025
Initiates: Outperform
Price Target: $13
Current: $4.82
Upside: +169.71%
GeoVax Labs
Aug 19, 2024
Maintains: Outperform
Price Target: $6$10
Current: $0.38
Upside: +2,551.82%
Unicycive Therapeutics
Feb 14, 2024
Initiates: Outperform
Price Target: $60
Current: $6.23
Upside: +863.08%
Cadrenal Therapeutics
Dec 18, 2023
Initiates: Outperform
Price Target: $60
Current: $10.18
Upside: +489.39%
Eledon Pharmaceuticals
Sep 27, 2023
Initiates: Outperform
Price Target: $10
Current: $1.58
Upside: +532.91%
MAIA Biotechnology
Feb 21, 2023
Initiates: Outperform
Price Target: $14
Current: $1.20
Upside: +1,066.67%
Lineage Cell Therapeutics
Aug 19, 2021
Initiates: Outperform
Price Target: $8
Current: $1.72
Upside: +365.12%
Plus Therapeutics
Jan 25, 2021
Initiates: Buy
Price Target: $120
Current: $0.65
Upside: +18,361.54%
Benitec Biopharma
Oct 5, 2020
Downgrades: Neutral
Price Target: n/a
Current: $13.58
Upside: -
Initiates: Buy
Price Target: $12
Current: $4.40
Upside: +172.73%
Initiates: Buy
Price Target: $9,900,000
Current: $6.60
Upside: +149,999,900.00%
Downgrades: Neutral
Price Target: n/a
Current: $27.35
Upside: -
Initiates: Buy
Price Target: $15
Current: $3.80
Upside: +294.74%